FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a chimeric protein for inducing and/or alleviating immune response induced by herpes virus infection, a synthetic nucleic acid which is DNA, a vector comprising said DNA, a host cell for producing a chimeric protein, a method of producing said vector, a vaccine for inducing an immune response to herpes virus infection, containing said chimeric protein, and a vaccine for inducing an immune response to herpes virus infection containing said DNA. In one embodiment, the chimeric protein comprises a sequence, which is homologous to at least 70 % SEQ ID NO: 4.
EFFECT: invention extends the range of products for inducing an immune response to herpes virus infection.
24 cl, 2 dwg, 1 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
CHIMERIC PROTEIN L1 OF PAPILLOMAVIRUS | 2020 |
|
RU2808002C2 |
FUSION PROTEIN | 2016 |
|
RU2748643C2 |
RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
CHIMERIC PROTEIN | 2016 |
|
RU2746755C2 |
BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
HERPES VIRUS WITH A MODIFIED SPECTRUM OF TARGETS CONTAINING HYBRID GLYCOPROTEIN H | 2016 |
|
RU2732120C2 |
PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
MODULATION OF REP PROTEIN ACTIVITY WHEN PRODUCING CLOSED-END DNA (ceDNA) | 2020 |
|
RU2812850C2 |
RSV F MUTANT PROTEIN AND ITS APPLICATION | 2020 |
|
RU2807742C1 |
FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
Authors
Dates
2020-11-17—Published
2016-11-18—Filed